As Bristol Myers Squibb rolls ahead with its plan to cut $1.5 billion in costs by the end of the year, the drugmaker is once ...
Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. | Bristol Myers Squibb is levering Fulcrum ...
Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...
US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus ...
Nearly 300 employees in Lawrenceville will lose their jobs as part of a pharmaceutical company's major cost-cutting measures, ...
Shortly after bringing in a former FDA official to serve as its chief medical officer, Pfizer’s latest leadership appointment ...
The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...
Ongoing strategic partnership advances joint pipeline in neurodegeneration research• Evotec receives a $20 million payment to further progress research ...
Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult ...
Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on Friday ...
Bristol-Myers Squibb (NYSE:BMY) recently declared a quarterly dividend of $0.62 per share on its common stock, reinforcing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback